TABLE 4.
MRM parameters for kynurenine, quinoxaline, and AGE assays
DP, declustering potential; CE, collision energy; CXP, cell exit potential.
| tR | m/z | DP | m/z | CE | CXP | m/z | CE | CXP | m/z | CE | CXP | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| min | V | eV | V | eV | V | eV | V | |||||
| Kynurenines (method 1) | ||||||||||||
| 3OHKG | 2.19 | 387.1 | 78 | 208.0 | 22.9 | 10.3 | 370.1 | 16.6 | 28.4 | 225.1 | 19.4 | 8.8 |
| 3OHKyn | 1.46 | 225.1 | 30 | 110.0 | 20.0 | 3.9 | 162.0 | 30.2 | 7.9 | 190.1 | 23.1 | 6.2 |
| Kyn | 1.30 | 208.9 | 30 | 93.9 | 18.8 | 8.4 | 145.9 | 29.0 | 9.6 | 136.0 | 19.7 | 7.0 |
| Kynoxazine | 1.47 | 309.0 | 72 | 292.0 | 14.9 | 122.1 | 274.0 | 19.0 | 15.0 | 246.0 | 23.3 | 7.8 |
| 7-Azatryptophan | 2.09 | 206.0 | 35 | 130.9 | 43.7 | 8.7 | 132.1 | 28.7 | 9.0 | 145.0 | 24.8 | 8.0 |
| Quinoxalines (method 2) | ||||||||||||
| DHA-Q1 | 1.41 | 247.1 | 72 | 229.0 | 13.0 | 8.9 | 201.0 | 20.0 | 7.6 | 161.0 | 23.3 | 5.3 |
| DHA-Q2 | 1.89 | 355.0 | 36 | 109.0 | 18.0 | 12.2 | 246.9 | 14.6 | 15.7 | 337.0 | 17.3 | 15.1 |
| 2,3-DKG-Q | 1.37 | 265.0 | 27 | 185.1 | 21.1 | 6.5 | 161.1 | 26.3 | 5.6 | 156.9 | 32.1 | 5.2 |
| 3-DT-Q | 1.76 | 175.1 | 60 | 157.0 | 21.9 | 10.9 | 129.0 | 34.0 | 11.6 | 145.0 | 22.0 | 10.3 |
| AGEs (method 3) | ||||||||||||
| CML | 1.59 | 205.1 | 40 | 84.1 | 25 | 13 | 130.1 | 17 | 11 | 56.1 | 50 | 10 |
| DT-Ha | 1.45 | 259.1 | 60 | 144.1 | 22.0 | 10.1 | 70.0 | 43.0 | 7.0 | 114.0 | 34.0 | 8.0 |
| DT-Hb/DT-Hc | 1.49 | 259.1 | 60 | 144.1 | 22.0 | 10.1 | 70.0 | 43.0 | 7.0 | 116.1 | 24.9 | 8.1 |
| DOTDIC | 2.25 | 387.1 | 100 | 342.1 | 35.8 | 12.8 | 297.0 | 46.3 | 11.6 | 227.1 | 44.7 | 11.8 |